AU2002365504A1 - Injection solution comprising an lhrh antagonist - Google Patents
Injection solution comprising an lhrh antagonist Download PDFInfo
- Publication number
- AU2002365504A1 AU2002365504A1 AU2002365504A AU2002365504A AU2002365504A1 AU 2002365504 A1 AU2002365504 A1 AU 2002365504A1 AU 2002365504 A AU2002365504 A AU 2002365504A AU 2002365504 A AU2002365504 A AU 2002365504A AU 2002365504 A1 AU2002365504 A1 AU 2002365504A1
- Authority
- AU
- Australia
- Prior art keywords
- lhrh antagonist
- injection solution
- aqueous injection
- acid
- aqueous
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
- A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/36—Antigestagens
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Reproductive Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Manufacturing Of Micro-Capsules (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
VERIFICATION OF TRANSLATION RWS Group plc, of Europa House, Marsham Way, Gerrards Cross, Buckinghamshire, England, declare as follows: 1. That the translator responsible for the attached translation is well acquainted with both the English and German languages, and 2. That the attached document is a true and correct translation to the best of RWS Group plc knowledge and belief of: (a) The specification of International Bureau pamphlet numbered WO 03/045419 international Application No. PCT/EPO2/12798. Date: 14 May 2004 Signature: _ __ C. E. SITCH Deputy Managing Director - UK Translation Division For and on behalf of RWS Group plc (No witness required) (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International publication date (10) International publication number 5 June 200oo3 (05.06.2oo003) PCT WO 03/045419 Al (51) International patent classification': A61K 38/09, (81) Designated states (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, 9/08,47/26 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR. HU, ID. IL, IN, IS. JP. (21) International application number: PCT/EP02/12798 KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, (22) International filing date: 15 November 2002 (15.11.2002) OM, PH, PL, PT, RO, RU, SD. SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, (25) Language of filing: German ZM, ZW. (26) Language of publication: German (84) Designated states (regional): ARIPO Patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), (30) Data relating to the priority: Eurasian Patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, 101 57 628.5 26 November 2001 (26.11.2001) DE TM), European Patent (AT, BE, BG, CH, CY, C7Z, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, (71) Applicant: ZENTARIS AG [DE/DE]; Weismtllerstrasse 45 SE, SK, TR), OAPI Patent (BF, BJ, CF, CG, CI, CM, 60314 Frankfurt (DE). GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG). (72) Inventors: SARLIKIOTIS, Werner; Sp. Dima 31, GR-190 02 Published: Peania (GR). BAUER, Horst; Rahrenstrasse 12a, 91217 With the International Search Report. Hersbruck (DE). RISCHER, Matthias; Schlesierstrasse 20, 60388 Frankfurt (DE). ENGEL, Jurgen; Erlenweg 3, 63755 For an explanation of the two-letter codes and the other Alzenau (DE). GVTHLEIN, Frank; Westendstrasse 5, 63477 abbreviations, reference is made to the explanations Maintal (DE). DI STEFANO, Dominique; Am B6rnchen 14, ("Guidance Notes on Codes and Abbreviations") at the 65479 Raunheim (DE). beginning of each regular edition of the PCT Gazette. As printed (54.) Title: INJECTION SOLUTION COMPRISING AN LHRH ANTAGONIST (54) Bezeichnung: INJEKTIONSLOSUNG EINES LHRIH-ANTAGONISTEN , (57) Abstract: The aqueous injection solution comprising an LHRH antagonist contains in addition to the LHRH antagonist, such If) as cetrorelix, an organic, physiologically compatible acid and optionally a surfactant and also a framework builder. The LHRH ' antagonist has significantly improved solubility and can be prepared in higher concentrations and with an improved bioavailability. The aggregation tendency of the LHRH antagonist is significantly reduced. (57) Zusammenfassuag: Die wlissrige Injektionslsung eines LHRH-Antagonisten enthklt neben dem LHRH-Antagonisten, wie Cetrorelix eine organische, physiologisch vertrigliche Siure, und ggf. ein Tensid sowie einen Gerdstbildner. Der LHRH-Antagonist ~ weist eine deutlich verbesserte Lislichkeit auf, kann in einer hBheren Konzentration und besseren BioverfUgbarkeit bereitgestelit werden. Die Aggregationsneigung des LHRH-Antagonisten wird deutlich herabgesetzt.
WO 03/045419 PCT/EPO2/12798 Injection solution of an LHRH antagonist Technical field: s The invention relates to aqueous injection solutions of an LHRH antagonist using additions of organic, physiologically tolerable acids and/or surfactants and their preparation for prevention of the aggregation of the LHRH antagonist in solution. The injection solutions prepared according to the invention additionally lead to an increase in the bioavailability and make 10 possible the lowering of the injection volume to be administered. Prior art: In controlled ovarian stimulation followed by egg cell removal and 15 techniques of assisted reproduction, besides LHRH agonists (e.g. triptorelin, buserelin), LHRH antagonists (cetrorelix, ganirelix) have especially been used for some time, since they avoid the initial increase in endogenous gonadotropin secretion and immediately lead to a competitive inhibition of gonadotropin-releasing hormone [EP 0 788 799 A2; EP 0 299 20 402 B1]. The LHRH antagonist ganirelix is at present used in a formulation which contains 0.25 mg of ganirelix in 0.5 ml of an aqueous, mannitol containing solution in the form of a ready-to-use injection (Orgalutran®). The LHRH antagonist cetrorelix (Cetrotide®) is at present supplied in two administration forms: a lyophilizate containing 0.25 mg of cetrorelix 25 combined with a ready-to-use syringe which contains 1 ml of water for reconstitution, and a lyophilizate containing 3 mg of cetrorelix combined with a ready-to-use syringe which contains 3 ml of water for reconstitution. LHRH antagonists, however, are not only used for controlled ovarian stimulation, but can also be used for the therapy of hormone-dependent 30 types of cancer such as, for example, prostate carcinoma. Substances such as abarelix [WO 98/25642] or cetrorelix [WO 00/47234] could be used for this in that the LHRH antagonists could be an alternative to the market dominating agonists (leuprolide, goserelin) in this therapy. On account of the relatively poor solubility of abarelix in water or physiological media, a 35 depot formulation must be used in order to achieve a long-term action. There are indications, however, that a long-term action could also be caused by good solubility of the LHRH antagonists [G. Jiang, J. Stakewski, R. Galyean, J. Dykert, C. Schteingart, P. Broqua, A. Aebi, M. L. Aubert, j, -2 G. Semple, P. Robson, K. Akinsanya, R. Haigh, P. Riviere, J. Trojnar, J. L. Junien and J. E. Rivier, J. Med. Chem., 2001, 44, 453-467]. Presentation of the invention: 5 It is the object of the invention to prepare an injection solution which achieves a low injection volume together with an increased concentration of the LHRH antagonist by means of its improved solubility. At the same time, the aggregation of the LHRH antagonist in the relatively highly 10 concentrated injection solution should be prevented. It has surprisingly been found that organic, physiologically tolerable acids, particularly carboxylic acids, in particular hydroxycarboxylic acids, but preferably gluconic acid on its own or in combination with surfactants such 15 as, for example, Tween, markedly improve the solubility of LHRH antagonists and thus markedly reduce the proneness to aggregation of these substances. The invention therefore makes it possible to prepare LHRH antagonists in relatively high concentration in aqueous solutions for injection. LHRH 20 antagonists which may be mentioned are, for example, cetrorelix, teverelix, D-63 153 (Ac-D-Nal-pCi-D-Phe-3-D-Pal-Ser-N-Me-Tyr-D-H-Cit-Iso-Leu Arg-Pro-D-Ala-NH2) ganirelix, abarelix, antide, azaline B. It was seen that an excess of the respective carboxylic acid must be used; equimolar amounts are not sufficient. Obviously, this effect cannot be explained alone 25 by an in-situ salt formation with basic amino acid residues present such as, for example, arginine, pyridylalanine, lysine. Likewise, the surfactant concentration must not be chosen to be too high, since otherwise the solutions foam too much and aggregation is in turn induced by the surfactants. 30 At the same time, these additions make possible an increase in the bioavailability, since they obviously also slow the spontaneous aggregation in the body after injection or make possible a more rapid absorption of the substance from the site of action. It was seen that the lowered pH of such injection solutions (e.g. pH = 2.5-3) has no influence on the local tolerability 35 of the injection. By increasing the concentration, it is possible to reduce the volume administered, e.g. in the case of cetrorelix from 3 ml to 1 ml for the 3 mg form. It was likewise shown that by means of these additions a good storage stability can be achieved (see Example 1). Although storage for over 6 months at 25°C/60% produced an increase in the impurities, the -3 content value in each case was still clearly above 90% (as a rule the lowest value of the use period specification of pharmaceutical products). The turbidity, as a sign of aggregation, increased only slightly. Turbidity values of up to 8 FTU (formazine turbidity unit according to European 5 Pharmacopoeia) are perfectly tolerable. Preservatives such as, for example, phenol or p-chloro-m-cresol do not interfere and can additionally be used for the preservation of the solutions. The use of customary bulking agents, such as mannitol, lactose, glucose and fructose, is likewise possible. 10 Description of a route for carrying out the invention: Example 1 15 500 mg of cetrorelix 2 g of Tween 80 2.4 g of gluconic acid delta-lactone 95 g of mannitol 20 were mixed with water for injection to 2 litres to give a homogeneous solution. The solution was then sterile-filtered and dispensed into ampoules. The ampoules were investigated analytically for purity (HPLC), content (HPLC), pH and aggregation (turbidity) initially and after a storage 25 time of 6 months at 2-8 0 C and 25°C/60% rel. humidity. Analytical results: Starting Investigation Investigation investigation after 6 months after 6 months at 2-80C at 250C/60% rel. humidit Purity [%] 0.37 0.69 2.32 Content [%] 100.0 98.7 95.4 pH 3.12 3.16 3.16 Turbidity [FTU] 1.88 2.62 3.92 -4 Example 2 About 500 mg of D-63153 About 100 mg of Tween 80 About 475 mg of mannitol 5 were adjusted to a pH of about 2.5 using aqueous, saturated gluconic acid delta-lactone solution. A volume of about 50 ml resulted. The mixture was stirred until a clear solution resulted. 10 Analytical results: The turbidity of the solution was initially 2.4 FTU. After 24 h, 2.1 FTU were measured. The purity profile and the content of the solution (HPLC) remained unchanged. 15 Structure of the LHRH antagonist D-63153: Ac-D-Nal-pCI-D-Phe-3-D-Pal-Ser-N-Me-Ty r- D- H
-
C it- Iso- Le u -A rg -P r o
-D
Ala-NH2 20 About 100 mg of teverelix About 100 mg of Tween 80 About 475 mg of mannitol 25 were adjusted to a pH of about 2.5 using aqueous, saturated gluconic acid delta-lactone solution. A volume of about 10 ml resulted. The mixture was stirred until a clear solution resulted. 30 Analytical results: The turbidity of the solution was initially 6.8 FTU. After 24 h, 8.4 FTU were measured. The purity profile and the content of the solution (HPLC) remained unchanged. 35 Structure of the LHRH antagonist teverelix: Ac-D-Nal-pCI-D-Phe-3-D-Pal-Ser-Ty r-D -H-C it
-
Le u -iP r-Lys -P r o - D-Ala - NH2
Claims (6)
- 2. Aqueous injection solution according to Claim 1, characterized in that a carboxylic acid is added. 10 3. Aqueous injection solution according to Claims 1 and 2, characterized in that a hydroxycarboxylic acid is added.
- 4. Aqueous injection solution according to Claims 1 to 3, characterized in that gluconic acid is added. 15 15 5. Aqueous injection solution according to Claims 1 to 4, characterized in that a surfactant is added.
- 6. Aqueous injection solution according to Claims 1 to 5, which 20 contains Tween as a surfactant.
- 7. Aqueous injection solution according to Claim 1, which as LHRH antagonist contains cetrorelix, teverelix, D-63 153 (Ac-D-Nal-pCI-D Phe-3-D-Pal-Ser-N-Me-Tyr-D-H-Cit-Iso-Leu-Arg-Pro-D-Ala-NH2), 25 ganirelix, abarelix, antide or azaline B.
- 8. Aqueous injection solution according to Claims 1 to 4, characterized in that the acid is present in an at least equimolar amount, based on the amount of the LHRH antagonist. 30 3 9. Aqueous injection solution of an LHRH antagonist according to Claims 1 to 8, comprising 500 mg of cetrorelix 2.4 g of gluconic acid delta-lactone 2.0 g of Tween 80 35
- 95.0 g of mannitol in 2 1 of water for injection. -6 10. Aqueous injection solution of an LHRH antagonist according to Claims 1 to 8, comprising 500 mg of D-63 153 100 mg of Tween 80 475 mg of mannitol 5 adjusted to 50 ml using saturated gluconic acid delta-lactone solution. 11. Aqueous injection solution of an LHRH antagonist according to Claims 1 to 8, comprising 100 mg of teverelix 10 100 mg of Tween 80 475 mg of mannitol adjusted to 10 ml using saturated gluconic acid delta-lactone solution. 15 12. Process for the preparation of aqueous injection solutions of an LHRH antagonist, characterized in that, alternatively -an LHRH antagonist, an organic, physiologically tolerable acid and optionally a surfactant and a bulking agent are dissolved in water for injection, homogenized and processed for injection purposes, or 20 -an LHRH antagonist and optionally a surfactant and a bulking agent are dissolved using an aqueous saturated solution of an organic, physiologically tolerable acid, homogenized and processed for injection purposes. 25 13. Process according to Claim 12, characterized in that a carboxylic acid, in particular hydroxycarboxylic acid, but preferably gluconic acid, is employed.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10157628.5 | 2001-11-26 | ||
DE10157628A DE10157628A1 (en) | 2001-11-26 | 2001-11-26 | Solution for injection of an LHRH antagonist |
PCT/EP2002/012798 WO2003045419A1 (en) | 2001-11-26 | 2002-11-15 | Injection solution comprising an lhrh antagonist |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2002365504A1 true AU2002365504A1 (en) | 2003-06-10 |
AU2002365504B2 AU2002365504B2 (en) | 2007-06-28 |
Family
ID=7706799
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2002365504A Expired AU2002365504B2 (en) | 2001-11-26 | 2002-11-15 | Injection solution comprising an LHRH antagonist |
Country Status (33)
Country | Link |
---|---|
EP (1) | EP1448221B1 (en) |
JP (1) | JP4343693B2 (en) |
KR (1) | KR100936636B1 (en) |
CN (1) | CN100404068C (en) |
AR (1) | AR037424A1 (en) |
AT (1) | ATE350050T1 (en) |
AU (1) | AU2002365504B2 (en) |
BR (1) | BRPI0214412B8 (en) |
CO (1) | CO5580793A2 (en) |
CY (1) | CY1106401T1 (en) |
DE (2) | DE10157628A1 (en) |
DK (1) | DK1448221T3 (en) |
EA (1) | EA010787B1 (en) |
ES (1) | ES2276970T3 (en) |
GE (1) | GEP20063861B (en) |
HK (1) | HK1073078A1 (en) |
HR (1) | HRP20040587B1 (en) |
HU (1) | HU230992B1 (en) |
IL (2) | IL161894A0 (en) |
IS (1) | IS2725B (en) |
ME (1) | ME00499B (en) |
MX (1) | MXPA04005018A (en) |
NO (1) | NO333364B1 (en) |
NZ (1) | NZ533712A (en) |
PL (1) | PL206199B1 (en) |
PT (1) | PT1448221E (en) |
RS (1) | RS51408B (en) |
RU (1) | RU2322969C2 (en) |
SI (1) | SI1448221T1 (en) |
TW (1) | TWI312283B (en) |
UA (1) | UA81612C2 (en) |
WO (1) | WO2003045419A1 (en) |
ZA (1) | ZA200404051B (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7658938B2 (en) | 1999-02-22 | 2010-02-09 | Merrion Reasearch III Limited | Solid oral dosage form containing an enhancer |
US8119159B2 (en) | 1999-02-22 | 2012-02-21 | Merrion Research Iii Limited | Solid oral dosage form containing an enhancer |
BRPI0710503A2 (en) | 2006-04-07 | 2011-08-16 | Merrion Res Iii Ltd | use of a pharmaceutical composition, pharmaceutical composition, and oral dosage form |
US8999383B2 (en) * | 2008-05-07 | 2015-04-07 | Merrion Research Iii Limited | Compositions of GnRH related compounds and processes of preparation |
US9089484B2 (en) | 2010-03-26 | 2015-07-28 | Merrion Research Iii Limited | Pharmaceutical compositions of selective factor Xa inhibitors for oral administration |
BR112013017169A2 (en) | 2011-01-07 | 2016-10-04 | Merrion Res Iii Ltd | iron pharmaceutical compositions for oral administration |
CN103690560B (en) * | 2013-12-17 | 2016-08-17 | 辽宁海思科制药有限公司 | A kind of Invert sugar electrolyte injection pharmaceutical composition and preparation method thereof |
US10265384B2 (en) | 2015-01-29 | 2019-04-23 | Novo Nordisk A/S | Tablets comprising GLP-1 agonist and enteric coating |
RU2614234C2 (en) * | 2015-03-31 | 2017-03-23 | Федеральное государственное бюджетное учреждение науки Институт общей генетики им. Н.И. Вавилова Российской академии наук (ИОГЕН РАН) | PHARMACEUTICAL COMPOSITION BASED ON 3-(4-METHYLIMIDAZOLE-1-YL)IMIDAZO[1,2-b][1,2,4,5]TETRAZINE AS ANTI-TUMOR AGENT |
KR20210157482A (en) * | 2017-01-30 | 2021-12-28 | 안테브 리미티드 | A composition comprising at least one GNRH antagonist |
HRP20211890T1 (en) | 2019-10-24 | 2022-03-04 | Sun Pharmaceutical Industries Ltd | A stable parenteral dosage form of cetrorelix acetate |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4800191A (en) * | 1987-07-17 | 1989-01-24 | Schally Andrew Victor | LHRH antagonists |
US5140009A (en) * | 1988-02-10 | 1992-08-18 | Tap Pharmaceuticals, Inc. | Octapeptide LHRH antagonists |
US5300492A (en) * | 1988-02-10 | 1994-04-05 | Tap Pharmaceuticals | LHRH analogs |
TR200200738T2 (en) * | 1999-09-23 | 2002-08-21 | Zentaris Ag | Therapeutic removal of endometrial tissue outside the uterus, chronic lower abdominal pain and fallopian tube obstruction. |
DE10024451A1 (en) * | 2000-05-18 | 2001-11-29 | Asta Medica Ag | Pharmaceutical dosage form for peptides, process for their preparation and use |
-
2001
- 2001-11-26 DE DE10157628A patent/DE10157628A1/en not_active Withdrawn
-
2002
- 2002-11-15 EA EA200400742A patent/EA010787B1/en unknown
- 2002-11-15 ME MEP-2008-800A patent/ME00499B/en unknown
- 2002-11-15 SI SI200230505T patent/SI1448221T1/en unknown
- 2002-11-15 CN CNB028234901A patent/CN100404068C/en not_active Expired - Lifetime
- 2002-11-15 RU RU2004119821/15A patent/RU2322969C2/en active
- 2002-11-15 KR KR1020047007807A patent/KR100936636B1/en active IP Right Grant
- 2002-11-15 GE GE5568A patent/GEP20063861B/en unknown
- 2002-11-15 ES ES02790384T patent/ES2276970T3/en not_active Expired - Lifetime
- 2002-11-15 JP JP2003546920A patent/JP4343693B2/en not_active Expired - Lifetime
- 2002-11-15 NZ NZ533712A patent/NZ533712A/en not_active IP Right Cessation
- 2002-11-15 DE DE50209193T patent/DE50209193D1/en not_active Expired - Lifetime
- 2002-11-15 DK DK02790384T patent/DK1448221T3/en active
- 2002-11-15 AT AT02790384T patent/ATE350050T1/en active
- 2002-11-15 UA UA20040503816A patent/UA81612C2/en unknown
- 2002-11-15 EP EP02790384A patent/EP1448221B1/en not_active Expired - Lifetime
- 2002-11-15 MX MXPA04005018A patent/MXPA04005018A/en active IP Right Grant
- 2002-11-15 HU HU0401986A patent/HU230992B1/en unknown
- 2002-11-15 PL PL369548A patent/PL206199B1/en unknown
- 2002-11-15 PT PT02790384T patent/PT1448221E/en unknown
- 2002-11-15 IL IL16189402A patent/IL161894A0/en unknown
- 2002-11-15 RS YUP-449/04A patent/RS51408B/en unknown
- 2002-11-15 WO PCT/EP2002/012798 patent/WO2003045419A1/en active IP Right Grant
- 2002-11-15 AU AU2002365504A patent/AU2002365504B2/en not_active Expired
- 2002-11-15 BR BRPI0214412A patent/BRPI0214412B8/en not_active IP Right Cessation
- 2002-11-20 TW TW091133846A patent/TWI312283B/en not_active IP Right Cessation
- 2002-11-25 AR ARP020104523A patent/AR037424A1/en not_active Application Discontinuation
-
2004
- 2004-05-06 IS IS7251A patent/IS2725B/en unknown
- 2004-05-10 IL IL161894A patent/IL161894A/en active IP Right Grant
- 2004-05-14 CO CO04044748A patent/CO5580793A2/en not_active Application Discontinuation
- 2004-05-25 ZA ZA2004/04051A patent/ZA200404051B/en unknown
- 2004-06-11 NO NO20042449A patent/NO333364B1/en not_active IP Right Cessation
- 2004-06-24 HR HR20040587A patent/HRP20040587B1/en not_active IP Right Cessation
-
2005
- 2005-07-11 HK HK05105809.5A patent/HK1073078A1/en not_active IP Right Cessation
-
2007
- 2007-03-20 CY CY20071100391T patent/CY1106401T1/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7790686B2 (en) | Injection solution of an LHRH antagonist | |
TW570811B (en) | Stabilized teriparatide solutions | |
AU2011304408B2 (en) | Caspofungin composition | |
AU2002365504B2 (en) | Injection solution comprising an LHRH antagonist | |
AU7404101A (en) | Pharmaceutical form of administration for peptides, methods for its production and use | |
DE102004063347A1 (en) | Ready-to-use gemcitabine solutions and gemcitabine solution concentrates | |
KR20140091652A (en) | A stable ready-to-use cetrorelix injection | |
EP1764102A1 (en) | Quinolone-containing medicinal composition | |
CN1187369C (en) | Method for producing peptide salts. their use, and pharmaceutical prepns. containing these peptide salts | |
IMAKI et al. | Amelioration of acromegaly after pituitary infarction due to gastrointestinal hemorrhage from gastric ulcer | |
JP2001163776A (en) | Stabilized liquid agent | |
CN102233130A (en) | Stable pharmaceutical preparation containing thymosin 1 derivatives | |
JPS62190122A (en) | Aqueous solution containing stable scopolamine hydrobromide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FGA | Letters patent sealed or granted (standard patent) | ||
PC | Assignment registered |
Owner name: ZENTARIS IVF GMBH Free format text: FORMER OWNER WAS: ZENTARIS GMBH |
|
MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |